GLMD
Price
$1.81
Change
+$0.02 (+1.12%)
Updated
Jun 27 closing price
Capitalization
4.11M
32 days until earnings call
RARE
Price
$36.52
Change
-$0.91 (-2.43%)
Updated
Jun 27 closing price
Capitalization
3.45B
32 days until earnings call
Interact to see
Advertisement

GLMD vs RARE

Header iconGLMD vs RARE Comparison
Open Charts GLMD vs RAREBanner chart's image
Galmed Pharmaceuticals
Price$1.81
Change+$0.02 (+1.12%)
Volume$112.66K
Capitalization4.11M
Ultragenyx Pharmaceutical
Price$36.52
Change-$0.91 (-2.43%)
Volume$2.68M
Capitalization3.45B
GLMD vs RARE Comparison Chart in %
Loading...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLMD vs. RARE commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLMD is a Buy and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (GLMD: $1.81 vs. RARE: $36.52)
Brand notoriety: GLMD and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLMD: 5% vs. RARE: 260%
Market capitalization -- GLMD: $4.11M vs. RARE: $3.45B
GLMD [@Biotechnology] is valued at $4.11M. RARE’s [@Biotechnology] market capitalization is $3.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLMD’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • GLMD’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, GLMD is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLMD’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 3 bullish TA indicator(s).

  • GLMD’s TA Score: 4 bullish, 4 bearish.
  • RARE’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, GLMD is a better buy in the short-term than RARE.

Price Growth

GLMD (@Biotechnology) experienced а -3.21% price change this week, while RARE (@Biotechnology) price change was -1.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

GLMD is expected to report earnings on Jul 31, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.45B) has a higher market cap than GLMD($4.11M). RARE YTD gains are higher at: -13.192 vs. GLMD (-43.260). GLMD has higher annual earnings (EBITDA): -6.07M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. GLMD (15.7M). GLMD has less debt than RARE: GLMD (41K) vs RARE (38.3M). RARE has higher revenues than GLMD: RARE (591M) vs GLMD (0).
GLMDRAREGLMD / RARE
Capitalization4.11M3.45B0%
EBITDA-6.07M-449.9M1%
Gain YTD-43.260-13.192328%
P/E Ratio0.02N/A-
Revenue0591M-
Total Cash15.7M494M3%
Total Debt41K38.3M0%
FUNDAMENTALS RATINGS
GLMD vs RARE: Fundamental Ratings
GLMD
RARE
OUTLOOK RATING
1..100
8673
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5160
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLMD's Valuation (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for RARE (79) in the Biotechnology industry. This means that GLMD’s stock grew somewhat faster than RARE’s over the last 12 months.

GLMD's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as RARE (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to RARE’s over the last 12 months.

GLMD's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as RARE (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to RARE’s over the last 12 months.

GLMD's Price Growth Rating (51) in the Pharmaceuticals Other industry is in the same range as RARE (60) in the Biotechnology industry. This means that GLMD’s stock grew similarly to RARE’s over the last 12 months.

GLMD's P/E Growth Rating (97) in the Pharmaceuticals Other industry is in the same range as RARE (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLMDRARE
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
73%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
76%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 17 days ago
90%
Bearish Trend 13 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ABLYX27.260.14
+0.52%
American Beacon Large Cap Value Y
ANFCX54.600.24
+0.44%
American Funds New Economy C
PIBQX18.320.05
+0.27%
PGIM Balanced R6
ASGTX5.200.01
+0.19%
Transamerica Small Cap Growth A
RGIAX10.27N/A
N/A
Russell Inv Global Infrastructure A

GLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLMD has been loosely correlated with HXBM. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GLMD jumps, then HXBM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLMD
1D Price
Change %
GLMD100%
+1.12%
HXBM - GLMD
38%
Loosely correlated
N/A
IOBT - GLMD
34%
Loosely correlated
-2.70%
REVB - GLMD
31%
Poorly correlated
-7.44%
ATHE - GLMD
30%
Poorly correlated
+0.34%
RARE - GLMD
30%
Poorly correlated
-2.43%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with CRNX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-2.43%
CRNX - RARE
52%
Loosely correlated
-0.10%
COGT - RARE
51%
Loosely correlated
-3.14%
DNLI - RARE
50%
Loosely correlated
-2.69%
RVMD - RARE
50%
Loosely correlated
-1.52%
NUVL - RARE
49%
Loosely correlated
+0.68%
More